6-Chlor-4-methyl-indan | 936-19-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 6-Chlor-4-methyl-indan
• 英文别名: 6-chloro-4-methyl-2,3-dihydro-1H-indene
• CAS: 936-19-6
• 化学式: C₁₀H₁₁Cl
• 分子量: 166.65
• InChiKey: OWABRXYPHLLUEJ-UHFFFAOYSA-N

物化性质

• 沸点：
  52-54 °C(Press: 0.05 Torr)
• 密度：
  1.135±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  6-Chlor-4-methyl-indan 在 吡啶 、 sodium hydroxide 作用下， 以 乙醚 、 乙二醇 为溶剂， 反应 36.0h， 生成
  参考文献：
  名称：

  Munavalli,S.; Ourisson,G., Bulletin de la Societe Chimique de France, 1964, p. 3103 - 3112

  摘要：

  DOI：
• 作为产物：
  描述：

  4-氯-2-甲基苯胺 在 吡啶 、 盐酸 、 sodium hydroxide 、 PPA 、 sodium amalgam 、 汞 、 锌 作用下， 生成 6-Chlor-4-methyl-indan
  参考文献：
  名称：

  Munavalli,S.; Ourisson,G., Bulletin de la Societe Chimique de France, 1964, p. 3103 - 3112

  摘要：

  DOI：

文献信息

• [EN] COMPOUNDS USEFUL FOR TREATING GASTROINTESTINAL TRACT DISORDERS<br/>[FR] COMPOSÉS UTILES POUR LE TRAITEMENT DE TROUBLES DU TRACTUS DIGESTIF
  申请人：ARDELYX INC

  公开号：WO2018129552A1

  公开（公告）日：2018-07-12

  The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist- induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.

  本公开涉及化合物和治疗与液体潴留或盐过多有关的疾病的方法，例如心力衰竭（特别是充血性心力衰竭）、慢性肾病、晚期肾病、肝病和过氧化物酶体增殖物激活受体（PPAR）γ激动剂诱导的液体潴留。本公开还涉及化合物和治疗高血压的方法。本公开还涉及化合物和治疗胃肠道疾病的方法，包括治疗或减轻与胃肠道疾病相关的疼痛。
• [EN] HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE.<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES POUR LE TRAITEMENT OU LA PRÉVENTION DE TROUBLES PROVOQUÉS PAR UNE NEUROTRANSMISSION RÉDUITE DE LA SÉROTONINE, DE LA NORÉPINEPHRINE OU DE LA DOPAMINE
  申请人：OTSUKA PHARMA CO LTD

  公开号：WO2012036253A1

  公开（公告）日：2012-03-22

  A heterocyclic compound represented by the general formula (1) or a salt thereof: wherein m, l, and n respectively represent an integer of 1 or 2; X represents -O- or -CH2-; R1 represents hydrogen, a lower alkyl group, a hydroxy-lower alkyl group, a protecting group, or a tri-lower alkylsilyloxy-lower alkyl group; R2 and R3, which are the same or different, each independently represent hydrogen or a lower alkyl group; or R2 and R3 are bonded to form a cyclo-C3-C8 alkyl group; and R4 represents an aromatic group or a heterocyclic group, wherein the aromatic or heterocyclic group may have one or more arbitrary substituent(s).

  通用式（1）表示的杂环化合物或其盐：其中m、l和n分别表示1或2的整数；X表示-O-或-CH2-；R1表示氢、较低的烷基基团、羟基较低的烷基基团、保护基或三较低烷氧基较低的烷基基团；R2和R3，相同或不同，各自独立地表示氢或较低的烷基基团；或R2和R3结合形成环-C3-C8烷基基团；R4表示芳香基团或杂环基团，其中芳香基团或杂环基团可能具有一个或多个任意取代基。
• [EN] CHIRAL SYNTHESIS OF A TERTIARY ALCOHOL<br/>[FR] SYNTHÈSE CHIRALE D'UN ALCOOL TERTIAIRE
  申请人：RECURIUM IP HOLDINGS LLC

  公开号：WO2021097139A1

  公开（公告）日：2021-05-20

  Disclosed herein are methods for preparing tertiary alcohols from an optionally substituted phenyl ketone or an optionally substituted pyridinyl ketone that includes the use of a chiral ligand and boron trifluoride diethyl etherate. Tertiary alcohols can be used to prepare synthetic versions of natural products and/or pharmaceuticals.

  本文披露了一种从可选择取代的苯基酮或可选择取代的吡啶基酮制备三级醇的方法，其中使用了手性配体和三氟化硼乙醚。三级醇可用于制备天然产物和/或药物的合成版本。
• Carbostyril compound
  申请人：Kuroda Takeshi

  公开号：US20070179173A1

  公开（公告）日：2007-08-02

  The present invention provides a carbostyril compound represented by General Formula (1) or a salt thereof, wherein A is a direct bond, a lower alkylene group, or a lower alkylidene group; X is an oxygen atom or a sulfur atom; R 4 and R 5 each represent a hydrogen atom; the bond between the 3 and 4 positions of the carbostyril skeleton is a single bond or a double bond; R 1 is a hydrogen atom, etc; R 2 is a hydrogen atom, etc; and R 3 is a hydrogen atom, etc. The carbostyril compound or salt thereof of the present invention induces the production of TFF, and thus is usable for the treatment and/or prevention of disorders such as alimentary tract diseases, oral diseases, upper respiratory tract diseases, respiratory tract diseases, eye diseases, cancers, and wounds.

  本发明提供了一种由通式（1）表示的碳基噻吩化合物或其盐，其中A是直接键，较低的烷基烷基或较低的烷基亚烷基；X是氧原子或硫原子；R4和R5分别表示氢原子；碳基噻吩骨架的3和4位之间的键是单键或双键；R1是氢原子等；R2是氢原子等；R3是氢原子等。本发明的碳基噻吩化合物或其盐能够诱导TFF的产生，因此可用于治疗和/或预防消化道疾病、口腔疾病、上呼吸道疾病、呼吸道疾病、眼部疾病、癌症和伤口等疾病。
• CARBOSTYRIL COMPOUND
  申请人：Kuroda Takeshi

  公开号：US20100261705A1

  公开（公告）日：2010-10-14

  The present invention provides a carbostyril compound represented by General Formula (1) or a salt thereof, wherein A is a direct bond, a lower alkylene group, or a lower alkylidene group; X is an oxygen atom or a sulfur atom; R 4 and R 5 each represent a hydrogen atom; the bond between the 3 and 4 positions of the carbostyril skeleton is a single bond or a double bond; R 1 is a hydrogen atom, etc; R 2 is a hydrogen atom, etc; and R 3 is a hydrogen atom, etc. The carbostyril compound or salt thereof of the present invention induces the production of TFF, and thus is usable for the treatment and/or prevention of disorders such as alimentary tract diseases, oral diseases, upper respiratory tract diseases, respiratory tract diseases, eye diseases, cancers, and wounds.

  本发明提供了一种由通式（1）表示的羧基苯基咔唑化合物或其盐，其中A表示直接键，较低的烷基烷基或较低的烷基亚甲基烷基；X表示氧原子或硫原子；R4和R5各代表氢原子；羧基苯基咔唑骨架的3和4位置之间的键是单键或双键；R1是氢原子等；R2是氢原子等；R3是氢原子等。本发明的羧基苯基咔唑化合物或其盐可诱导TFF的产生，因此可用于治疗和/或预防消化道疾病、口腔疾病、上呼吸道疾病、呼吸道疾病、眼部疾病、癌症和创伤等疾病。